Catalyst Pharmaceuticals (CPRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CPRX Catalyst Pharmaceuticals

Watchlist

18.300
+2.070+12.75%

Close Aug 8 16:00 ET

18.500
+0.200+1.09%

Post 16:13 ET

2.17BMarket Cap32.68P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Call Summary | Catalyst Pharmaceuticals(CPRX.US) Q2 2024 Earnings Conference
moomoo AI50minutes ago · Conference Call
Express News | Catalyst Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results
Benzinga14:20 ET
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript
Earnings Call Transcripts13:30 ET
Express News | Catalyst Pharmaceuticals Inc : Piper Sandler Raises Target Price to $27 From $26
ReutersAug 8 11:21 ET
Catalyst Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
SEC announcementAug 7 22:16 ET · Announcements
Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Reports Q2 Revenue $122.7M, Vs. Street Est of $111.9M
MT NewswiresAug 7 16:36 ET

Comments

Trytosaveabit

Jul 24 07:12

Update

$Catalyst Pharmaceuticals (CPRX.US)$ Catalyst Pharmaceuticals Enters Exclusive License, Supply And Commercialization Agreement Granting Kye Pharmaceuticals Canadian Rights To AGAMREE For Duchenne Muscular Dystrophy

Meltyy

May 24 03:20

See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...

Trytosaveabit

May 8 15:21

Solid

$Catalyst Pharmaceuticals (CPRX.US)$ May 08 (Reuters) - Catalyst Pharmaceuticals Q1 Net Income USD 23.3 Million.
Q1 Adjusted Net Income USD 46.8 Million Vs. Ibes Estimate USD 23.7 Million
Q1 Operating Income USD 27.1 Million Vs. Ibes Estimate USD 25.1 Million
Outlook FY Revenue USD 455-475 Million

Moomoo AI

Mar 22 09:45

The absence of insider buying at Catalyst Pharmaceuticals over the past year is concerning. However, the high level of insider ownership indicates alignment with shareholder interests. Insider selling, even below the current price, raises questions about their view on the company's valuation.